Giperfosfatemiya pri khronicheskoy bolezni pochek: sovremennaya strategiya korrektsii
- 作者: Volgina G.1, Shtandel' V.1, Balkarova O.1, Lovchinskiy E.1
-
隶属关系:
- 期: 卷 23, 编号 7 (2012)
- 页面: 19-23
- 栏目: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115425
- ID: 115425
如何引用文章
详细
Рассматриваются механизмы нарушения минерального гомеостаза у пациентов с хронической болезнью почек (ХБП). Показано, что ранний и эффективный контроль минерально-костного метаболизма как на додиализной стадии, так и при лечении диализом - это ключ к успешному управлению ХБП.
全文:
参考
- Moe S., Chertow G. Chronic kidney disease-mineral-bone disorder: a new paradigm // Am. J. Kidney Dis. - 2007; 14 (1): 3-12.
- Alon U. Fibroblast growth factor (FGF)23: a new hormone // Eur. J. Pediatr. -2011; 170: 545-54.
- Gattineni J., Bates C., Twombley K. et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1 // Am. J. Physiol. Renal. Physiol. - 2009; 297: F282-F291.
- Farrow E., Davis S., Summers L. et al. Initial FGF23-mediated signaling occurs in the distal convoluted tubule // J. Am. Soc. Nephrol. - 2009; 20: 955-60.
- Hasegawa H., Nagano N., Urakawa I. et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease // Kidney Int. - 2010; 78: 975-80.
- Bergwitz C., Juppner H. Regulation of phosphate homeostasis by PTH, vitamin D, and FGF23 // Ann. Rev. Med. - 2010; 61: 91-104.
- Gutierrez O., Isakova T., Rhee E. et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease // J. Am. Soc. Nephrol. - 2005; 16: 2205-15.
- Shimada T., Hasegawa H., Yamazaki Y. et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis // J. Bone Miner. Res. - 2004; 19: 429-35.
- Krajisnik T., Bjorklund P., Marsell R. et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1α-hydroxylase expression in cultured bovine parathyroid cells // J. Endocrinol. - 2007; 195: 125-31.
- Kawata T., Imanishi Y., Kobayashi K. et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism // J. Am. Soc. Nephrol. - 2007; 18: 2683-8.
- Vervloet M., Larsson T. Fibroblast growth factor-23 and Klotho in chronic kidney disease // Kidney International Supplements. - 2011; 1: 130-5.
- Tentori F., Blayney M., Albert J. et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS) // Am. J. Kidney Dis. - 2008; 52: 519-30.
- Wald R., Sarnak M., Tighiouart H. et al. Disordered mineral metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study // Am. J. Kidney Dis. - 2008; 52: 531-40.
- Jean G., Terrat J., Vanel T. et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients // Nephrol. Dial. Transplant. - 2009; 24: 2792-6.
- Foley R., Collins A., Herzog C. et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults // J. Am. Soc. Nephrol. - 2009; 20: 397-404.
- Nasrallah M., El-Shehaby A., Salem M. et al. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients // Nephrol. Dial. Transplant. - 2010; 25: 2679-85.
- Block G., Hulbert-Shearon T., Levin N. et al. Association of serum phosphorus and calcium x phosphorus product with mortality risk in chronic hemodialysis patients: a national study // Am J Kidney Dis. - 1998; 31: 607-17.
- Block G., Klassen P., Lazarus J. et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis // J. Am. Soc. Nephrol. - 2004; 15: 2208-18.
- Kestenbaum B., Sampson J., Rudser K. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease // J. Am. Soc. Nephrol. -2005; 16: 520-8.
- Levin A., Bakris G., Molitch M. et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease // Kidney Int. - 2007; 71: 31-8.
- Dhingra R., Sullivan L., Fox C. et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community // Arch. Intern. Med. - 2007; 167: 879-85.
- Tonelli M., Sacks F., Pfeffer M. et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease // Circulation. -2005; 112: 2627-33.
- Tonelli M., Curhan G., Pfeffer M. et al. Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality // Circulation. - 2009; 120: 1784-92.
- Foley R., Collins A., Ishani A. et al. Calcium-phosphate levels and cardiovascular disease in communitydwelling adults: The Atherosclerosis Risk in Communities (ARIC) Study // Am. Heart. J. - 2008; 156: 556-63.
- de Boer I., Rue T., Kestenbaum B. Serum phosphorus concentrations in the third National Health and Nutrition Examination Survey (NHANES III) // Am. J. Kidney Dis. - 2009; 53: 399-407.
- Gutierrez O., Mannstadt M., Isakova T. et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis // N. Engl. J. Med. - 2008; 359: 584-92.
- Fliser D., Kollerits B., Neyer U. et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study // J. Am. Soc. Nephrol. - 2007; 18: 2600-8.
- Isakova T., Gutierrez O., Chang Y. et al. Phosphorus binders and survival on hemodialysis // J. Am. Soc. Nephrol. - 2009; 20: 388-96.